KAS
CADL icon

Kestra Advisory Services’s Candel Therapeutics CADL Stock Holding History

Kestra Advisory Services’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,500
Closed -$39K – 2266
2022
Q3 		$39K Hold
12,500
– – ﹤0.01% 2041
2022
Q2 		$41K Hold
12,500
– – ﹤0.01% 2052
2022
Q1 		$64K Buy
+12,500
New +$62.1K ﹤0.01% 1953

Other funds holding CADL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

Kestra Advisory Services's CADL Position: Q4 2022 in Review

Kestra Advisory Services sold out of Candel Therapeutics (CADL) in Q4 2022, closing a stake of 12,500 shares — an estimated $39K sold.

Kestra Advisory Services first reported a position in CADL in Q1 2022 and held it in 3 quarters. The position peaked at $64K in Q1 2022. 21 funds tracked by Wall St. Rank hold CADL as of Q4 2022.

  • Kestra Advisory Services reported no remaining Candel Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Kestra Advisory Services sold 12,500 Candel Therapeutics shares in Q4 2022, an estimated $39K.
  • Kestra Advisory Services first reported a position in Candel Therapeutics in Q1 2022 and held it in 3 quarters.
  • Kestra Advisory Services's Candel Therapeutics position peaked at $64K in Q1 2022.
  • 21 funds tracked by Wall St. Rank held Candel Therapeutics as of Q4 2022.

Based on Kestra Advisory Services's 13F filing for Q4 2022, filed 31 Jan 2023.